Recent Quotes (30 days)

You have no recent quotes
chg | %

Sunshine Biopharma, Inc.  

(Public, OTCMKTS:SBFM)   Watch this stock  
Find more results for OTC:SBFM
+0.015 (9.31%)
Apr 22 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.15 - 0.18
52 week 0.10 - 0.29
Open 0.16
Vol / Avg. 64,098.00/104,813.00
Mkt cap 10.87M
P/E     -
Div/yield     -
EPS -0.04
Shares 62.18M
Beta 16.86
Inst. own     -

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -612.74% -586.95%
Return on average equity -733.30% -816.41%
Employees 3 -
CDP Score - -


3rd Floor, 469 Jean-Talon West
+1-514-7649698 (Phone)
+1-514-7649699 (Fax)

Website links


Sunshine Biopharma, Inc. is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company�s lead compound, Adva-27a is a multi-purpose anti-tumor. Its drug candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer. As of December 31, 2011, the Company planned to conduct its Phase I clinical trials for Adva-27a. During the year ended December 31, 2011, the early stage preclinical studies for its lead compound, Adva-27a, were completed. As of December 31, 2011, the Company was focused on continuing its clinical development program of Adva-27a by conducting the next sequence of steps consist of the GMP Manufacturing (for use in IND-Enabling Studies and Phase I Clinical Trials); IND-Enabling Studies; Regulatory Filing (Fast-Track Status Anticipated), and Phase I Clinical Trials (Multidrug Resistant Breast Cancer Indication).

Officers and directors

Steve N. Slilaty Chairman of the Board, President, Chief Executive Officer
Age: 60
Camille Sebaaly Chief Financial Officer, Secretary, Director
Age: 53
Michele Di Turi Chief Operating Officer, Director
Age: 35